Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome

Cost-consequence Analysis of Influenza Vaccination Among the Staff of a Large Teaching Hospital in Rome, Italy: A Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06304038

Enrollment

5483

Registered

2024-03-12

Start date

2017-10-16

Completion date

2019-11-14

Last updated

2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cost-Benefit Analysis, Influenza Vaccine

Brief summary

Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity. Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low. The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days.

Interventions

DRUGFlu Vaccine

Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

• Healthcare workers at Fondazione Policlinico Universitario A.Gemelli IRCCS

Exclusion criteria

• Healthcare workers not working at Fondazione Policlinico Universitario A.Gemelli IRCCS

Design outcomes

Primary

Measure	Time frame	Description
Effectiveness of the quadrivalent vaccine	33 weeks	Effectiveness of the quadrivalent vaccine in reducing the number of working days lost due to influenza syndrome
Economic impact of the quadrivalent vaccine	33 weeks	Economic impact (for the company and society) of vaccination as part of a vaccination campaign on the healthcare workers of the teaching hospital.

Secondary

Measure	Time frame	Description
Expected economic savings for each one percentage point increase in vaccination coverage	33 weeks	Expected economic savings for each one percentage point increase in coverage on the health personnel of the teaching hospital
Non-economic incentives for healthcare personnel who decide to vaccinate	33 weeks	Non-economic incentives for healthcare personnel who decide to vaccinate, in view of the financial savings for the company, linked to increased vaccination coverage

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026